Showing 1 - 20 results of 30,456 for search '(( has a decrease ) OR ((( _ largest decrease ) OR ( a ((mean decrease) OR (_ decrease)) ))))', query time: 0.56s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Table 3_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.xlsx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  8. 8

    Table 1_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  9. 9

    Table 2_Multi-omics reveals that NOTCH1 promotes cervical cancer progression and reduces radiosensitivity.docx by Aihua Guo (13267712)

    Published 2025
    “…</p>Conclusions<p>This study clarifies NOTCH1’s role in promoting cervical cancer progression and reducing radiosensitivity, with has-miR-449a as a negative regulator, providing targets for optimizing cervical cancer radiotherapy.…”
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

    Published 2025
    “…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”
  17. 17
  18. 18
  19. 19

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”
  20. 20

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. …”